Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

TMB-H + PD-L1 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

PD-L1 expression (356)

PD-L1 overexpression (181)

PD-L1 underexpression (46)

PD-L1 negative (28)

HER-2 negative + PD-L1 expression (12)

HER-2 positive + PD-L1 expression (3)

HR negative + PD-L1 expression (2)

MSLN overexpression + PD-L1 overexpression (2)

PD-L1 expression + CD68 positive (2)

PD-L1 expression + HER-2 overexpression (2)

PD-L1 expression + PVR expression (2)

PD-L1 overexpression + CD8 overexpression (2)

TTF1 expression + PD-L1 expression (2)

miR-625-5p underexpression + PD-L1 overexpression (2)

AXL overexpression + PD-L1 expression (1)

CGAS overexpression + PD-L1 overexpression (1)

CMTM4 expression + PD-L1 expression (1)

CMTM6 expression + PD-L1 expression (1)

CMTM6 overexpression + PD-L1 overexpression (1)

CXCL12 expression + PD-L1 underexpression (1)

HLA-A underexpression + PD-L1 expression (1)

HR positive + PD-L1 expression (1)

IGFBP2 overexpression + PD-L1 overexpression (1)

MHC-II overexpression + PD-L1 negative (1)

MHC-II overexpression + PD-L1 underexpression (1)

NKX2-1 expression + PD-L1 expression (1)

NR1H4 overexpression + PD‑L1 underexpression (1)

NT5E overexpression + PD-L1 expression (1)

PD-1 underexpression + PD-L1 overexpression (1)

PD-L1 expression + CD14 positive (1)

PD-L1 expression + CD47 expression (1)

PD-L1 expression + CD8 negative + GZMB negative (1)

PD-L1 expression + CD8 positive (1)

PD-L1 expression + CTLA4 expression (1)

PD-L1 expression + MTOR overexpression (1)

PD-L1 expression + REV3L overexpression (1)

PD-L1 overexpression + APOBEC3B overexpression (1)

PD-L1 overexpression + CCL5 overexpression (1)

PD-L1 overexpression + CD163 underexpression (1)

PD-L1 overexpression + ER positive (1)

PD-L1 overexpression + GZMA overexpression (1)

PD-L1 overexpression + LAG3 expression + CTAG1B expression (1)

PD-L1 overexpression + PD-L2 underexpression (1)

PD-L1 overexpression + SOX2 overexpression (1)

RBM17 expression + PD-L1 expression (1)

RET positive + PD-L1 overexpression (1)

SNX20 overexpression + PD-L1 overexpression (1)

STK11 underexpression + PD-L1 overexpression (1)

TFRC overexpression + PD-L1 underexpression (1)

TNFSF4 overexpression + PD-L1 overexpression (1)

TTF1 expression + PD-L1 overexpression (1)

HER-2 negative + HR negative + PD-L1 expression (0)

PD-L1 expression + HER-2 expression (0)

PD-L1 expression + LAG3 expression (0)

PD-L1 expression + TTF1 expression (0)

TMB + PD-L1 expression (0)

PD-L1 expression (356)

PD-L1 overexpression (181)

PD-L1 underexpression (46)

PD-L1 negative (28)

HER-2 negative + PD-L1 expression (12)

HER-2 positive + PD-L1 expression (3)

HR negative + PD-L1 expression (2)

MSLN overexpression + PD-L1 overexpression (2)

PD-L1 expression + CD68 positive (2)

PD-L1 expression + HER-2 overexpression (2)

PD-L1 expression + PVR expression (2)

PD-L1 overexpression + CD8 overexpression (2)

TTF1 expression + PD-L1 expression (2)

miR-625-5p underexpression + PD-L1 overexpression (2)

AXL overexpression + PD-L1 expression (1)

CGAS overexpression + PD-L1 overexpression (1)

CMTM4 expression + PD-L1 expression (1)

CMTM6 expression + PD-L1 expression (1)

CMTM6 overexpression + PD-L1 overexpression (1)

CXCL12 expression + PD-L1 underexpression (1)

HLA-A underexpression + PD-L1 expression (1)

HR positive + PD-L1 expression (1)

IGFBP2 overexpression + PD-L1 overexpression (1)

MHC-II overexpression + PD-L1 negative (1)

MHC-II overexpression + PD-L1 underexpression (1)

NKX2-1 expression + PD-L1 expression (1)

NR1H4 overexpression + PD‑L1 underexpression (1)

NT5E overexpression + PD-L1 expression (1)

PD-1 underexpression + PD-L1 overexpression (1)

PD-L1 expression + CD14 positive (1)

PD-L1 expression + CD47 expression (1)

PD-L1 expression + CD8 negative + GZMB negative (1)

PD-L1 expression + CD8 positive (1)

PD-L1 expression + CTLA4 expression (1)

PD-L1 expression + MTOR overexpression (1)

PD-L1 expression + REV3L overexpression (1)

PD-L1 overexpression + APOBEC3B overexpression (1)

PD-L1 overexpression + CCL5 overexpression (1)

PD-L1 overexpression + CD163 underexpression (1)

PD-L1 overexpression + ER positive (1)

PD-L1 overexpression + GZMA overexpression (1)

PD-L1 overexpression + LAG3 expression + CTAG1B expression (1)

PD-L1 overexpression + PD-L2 underexpression (1)

PD-L1 overexpression + SOX2 overexpression (1)

RBM17 expression + PD-L1 expression (1)

RET positive + PD-L1 overexpression (1)

SNX20 overexpression + PD-L1 overexpression (1)

STK11 underexpression + PD-L1 overexpression (1)

TFRC overexpression + PD-L1 underexpression (1)

TNFSF4 overexpression + PD-L1 overexpression (1)

TTF1 expression + PD-L1 overexpression (1)

HER-2 negative + HR negative + PD-L1 expression (0)

PD-L1 expression + HER-2 expression (0)

PD-L1 expression + LAG3 expression (0)

PD-L1 expression + TTF1 expression (0)

TMB + PD-L1 expression (0)

›

TMB-H + PD-L1 overexpression	Non Small Cell Lung Cancer	TMB-H + PD-L1 overexpression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
TMB-H + PD-L1 overexpression	Non Small Cell Lung Cancer	TMB-H + PD-L1 overexpression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
TMB-H + PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck	TMB-H + PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
TMB-H + PD-L1 overexpression	Fibrosarcoma	TMB-H + PD-L1 overexpression	Fibrosarcoma	cisplatin + ifosfamide + epirubicin Resistant: C4 – Case Studies cisplatin + ifosfamide + epirubicin Resistant : C4	cisplatin + ifosfamide + epirubicin Resistant: C4 – Case Studies cisplatin + ifosfamide + epirubicin Resistant : C4
TMB-H + PD-L1 overexpression	Fibrosarcoma	TMB-H + PD-L1 overexpression	Fibrosarcoma	camrelizumab Sensitive: C4 – Case Studies camrelizumab Sensitive : C4	camrelizumab Sensitive: C4 – Case Studies camrelizumab Sensitive : C4
TMB-H + PD-L1 overexpression	Fibrosarcoma	TMB-H + PD-L1 overexpression	Fibrosarcoma	anlotinib Resistant: C4 – Case Studies anlotinib Resistant : C4	anlotinib Resistant: C4 – Case Studies anlotinib Resistant : C4
TMB-H + PD-L1 overexpression	Non Small Cell Lung Cancer	TMB-H + PD-L1 overexpression	Non Small Cell Lung Cancer	toripalimab-tpzi Sensitive: C4 – Case Studies toripalimab-tpzi Sensitive : C4	toripalimab-tpzi Sensitive: C4 – Case Studies toripalimab-tpzi Sensitive : C4